Accessibility Statement

Press Releases


U.S. Food and Drug Administration to Convene Advisory Committee Meeting to Discuss the TRAILBLAZER-ALZ 2 Study of Donanemab

March 8, 2024

Tags |  Product

INDIANAPOLIS , March 8, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) expects to convene a meeting of the Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) to discuss the Phase 3 TRAILBLAZER-ALZ 2 trial,




Lilly Announces Details of Presentations at 2024 American Association for Cancer Research (AACR) Annual Meeting

March 5, 2024

Tags |  Product

INDIANAPOLIS , March 5, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that preclinical data for agents targeting Nectin-4, KRAS G12D, and BRM (SMARCA2) will be presented at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 5-10 in San




Updated Data from the BRUIN Phase 1/2 Study of Pirtobrutinib in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma Presented at the 2023 ASH Annual Meeting

December 11, 2023

Tags |  Product

INDIANAPOLIS , Dec. 11, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced updated clinical data from the international Phase 1/2 BRUIN trial of pirtobrutinib, a non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor, in adult patients with a range of B-cell




Lilly's Zepbound™ (tirzepatide) achieved additional 6.7% weight loss following a 36-week open-label lead-in period, for a total mean weight loss of 26.0% from study entry over 88 weeks

December 11, 2023

Tags |  Product

People who were randomized to placebo following the lead-in period experienced mean weight regain of 14.8% at 88 weeks, indicating Zepbound led to sustained weight loss compared to placebo Full results from the SURMOUNT-4 study were published in The Journal of the American Medical Association




Lilly to Present Final Overall Survival Analysis from the MONARCH 3 Study of Verzenio® (abemaciclib) and Additional Results from Its Breast Cancer Portfolio at the 2023 San Antonio Breast Cancer Symposium

December 5, 2023

Tags |  Product

Results from MONARCH 3 show a numerical improvement in overall survival (OS) of 13.1 months for women with HR+, HER2- metastatic breast cancer treated with Verzenio plus an aromatase inhibitor in the intent-to-treat population and 14.9 months for women with visceral disease, however OS outcomes




Zepbound™ (tirzepatide) is Now Available in U.S. Pharmacies for Adults Living with Obesity

December 5, 2023

Tags |  Product

Express Scripts to add Zepbound to National Preferred Formulary INDIANAPOLIS , Dec. 5, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that Zepbound ™ (tirzepatide) injection is now available. Zepbound is indicated for adults with obesity (with a BMI of 30 kg/m 2 or greater),




Jaypirca® (pirtobrutinib) Now Approved by U.S. FDA for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Have Received at Least Two Lines of Therapy, Including a BTK Inhibitor and a BCL-2 Inhibitor

December 1, 2023

Tags |  Product

The first and only non-covalent (reversible) BTK inhibitor, Jaypirca has been shown to extend the benefit of BTK inhibition In the BRUIN Phase 1/2 trial,   adult patients with CLL/SLL who have received at least two lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor, achieved an




FDA Approves Lilly's Zepbound™ (tirzepatide) for Chronic Weight Management, a Powerful New Option for the Treatment of Obesity or Overweight with Weight-Related Medical Problems

November 8, 2023

Tags |  Product

Adults taking Zepbound in a clinical trial lost on average 48 lb. at the highest dose Zepbound is the first and only approved treatment activating two incretin hormone receptors, GIP and GLP-1, to tackle an underlying cause of excess weight INDIANAPOLIS , Nov. 8, 2023 /PRNewswire/ -- The U.S.




Lilly Announces Details of Pirtobrutinib Presentations in B-Cell Malignancies at 2023 ASH Annual Meeting

November 2, 2023

Tags |  Product

INDIANAPOLIS , Nov. 2, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from studies of pirtobrutinib, a non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor, will be presented at the 65th American Society of Hematology (ASH) Annual Meeting and




Hip-Hop Classic "It Takes Two" Takes on New Meaning in Remix to Elevate Importance of Testing for Kidney Disease

November 1, 2023

Tags |  Product

Boehringer Ingelheim and Lilly team up with hip-hop artist Rob Base for the launch of It Takes 2™ – a new health initiative  to educate healthcare professionals and adults at risk for kidney disease on the condition's unknown nature  and the benefits of complete testing Clinical guidelines